GNE-493
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H406599

CAS#: 1033735-94-2

Description: GNE-493 is potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitor with potential anticancer activity.


Chemical Structure

img
GNE-493
CAS# 1033735-94-2

Theoretical Analysis

Hodoodo Cat#: H406599
Name: GNE-493
CAS#: 1033735-94-2
Chemical Formula: C17H20N6O2S
Exact Mass: 372.14
Molecular Weight: 372.447
Elemental Analysis: C, 54.82; H, 5.41; N, 22.56; O, 8.59; S, 8.61

Price and Availability

Size Price Availability Quantity
5mg USD 550 2 Weeks
10mg USD 800 2 Weeks
25mg USD 1650 2 Weeks
Bulk inquiry

Synonym: GNE493; GNE-493; GNE 493

IUPAC/Chemical Name: 2-(2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)propan-2-ol

InChi Key: LEXMMFPAPDGYGZ-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H20N6O2S/c1-17(2,24)12-7-11-13(26-12)15(23-3-5-25-6-4-23)22-14(21-11)10-8-19-16(18)20-9-10/h7-9,24H,3-6H2,1-2H3,(H2,18,19,20)

SMILES Code: CC(O)(C1=CC2=NC(C3=CN=C(N)N=C3)=NC(N4CCOCC4)=C2S1)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:         

Biological target: GNE-493 is a potent, selective, and orally available dual pan-PI3-kinase/mTOR inhibitor with IC50s of 3.4 nM, 12 nM, 16 nM, 16 nM and 32 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR.
In vitro activity: In other primary prostate cancer cells (priCa-2 and priCa-3) and immortalized cell lines (LNCaP and PC-3), treatment with GNE-493 (250 nM) significantly increased the relative caspase-3 activity (Fig. 2G). In addition, the TUNEL positively stained nuclei ratio (Fig. 2H) was significantly increased, confirming apoptosis activation. Reference: Cell Death Discov. 2022 Mar 16;8(1):120. https://pubmed.ncbi.nlm.nih.gov/35296639/
In vivo activity: Figure 6A showed that in nude mice GNE-493 administration potently inhibited growth of the priCa-1 xenograft tumors. In addition, TBAR activity was significantly enhanced in GNE-493-treated tumor tissues (Fig. 6H), supporting oxidative injury response. Therefore GNE-493 oral administration blocked Akt-mTOR signaling, downregulated SphK1, induced ceramide accumulation, and oxidative injury in priCa-1 xenograft tissues. Reference: Cell Death Discov. 2022 Mar 16;8(1):120. https://pubmed.ncbi.nlm.nih.gov/35296639/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMF 20.0 53.70
DMF:PBS (pH 7.2) (1:1) 0.5 1.34
DMSO 45.0 120.82
Ethanol 1.1 2.95

Preparing Stock Solutions

The following data is based on the product molecular weight 372.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Jin L, Zhang W, Yao MY, Tian Y, Xue BX, Tao W. GNE-493 inhibits prostate cancer cell growth via Akt-mTOR-dependent and -independent mechanisms. Cell Death Discov. 2022 Mar 16;8(1):120. doi: 10.1038/s41420-022-00911-y. PMID: 35296639; PMCID: PMC8927604.
In vitro protocol: 1. Jin L, Zhang W, Yao MY, Tian Y, Xue BX, Tao W. GNE-493 inhibits prostate cancer cell growth via Akt-mTOR-dependent and -independent mechanisms. Cell Death Discov. 2022 Mar 16;8(1):120. doi: 10.1038/s41420-022-00911-y. PMID: 35296639; PMCID: PMC8927604.
In vivo protocol: 1. Jin L, Zhang W, Yao MY, Tian Y, Xue BX, Tao W. GNE-493 inhibits prostate cancer cell growth via Akt-mTOR-dependent and -independent mechanisms. Cell Death Discov. 2022 Mar 16;8(1):120. doi: 10.1038/s41420-022-00911-y. PMID: 35296639; PMCID: PMC8927604.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

 1: Sutherlin DP, Sampath D, Berry M, Castanedo G, Chang Z, Chuckowree I, Dotson J, Folkes A, Friedman L, Goldsmith R, Heffron T, Lee L, Lesnick J, Lewis C, Mathieu S, Nonomiya J, Olivero A, Pang J, Prior WW, Salphati L, Sideris S, Tian Q, Tsui V, Wan NC, Wang S, Wiesmann C, Wong S, Zhu BY. Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer. J Med Chem. 2010 Feb 11;53(3):1086-97. doi: 10.1021/jm901284w. PubMed PMID: 20050669.